Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: Longitudinal validation in a randomized trial

Journal of Viral Hepatitis

Volumn 9, Issue 2, 2002, Pages 128-133

  Poynard, Thierry ^a   Imbert Bismut, F ^a   Ratziu, V ^a,b   Chevret, S ^c   Jardel, C ^a   Moussalli, J ^a   Messous, D ^a   Degos, F ^d  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b EUROPEAN SPACE AGENCY   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d BEAUJON HOSPITAL   (France)

Author keywords

Fibrosis; Hepatitis C; Liver biopsy; Paired biopsies; Serum markers

Indexed keywords

ALPHA 2 MACROGLOBULIN; ALPHA INTERFERON; APOLIPOPROTEIN A1; BILIRUBIN; BIOCHEMICAL MARKER; GAMMA GLUTAMYLTRANSFERASE; HAPTOGLOBIN; HYALURONIC ACID; INTERFERON;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; FEMALE; FIBROSIS; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; RETROSPECTIVE STUDY; SAMPLING; TIME; VALIDATION PROCESS;

ADULT; AGED; ALPHA-MACROGLOBULINS; ANTIVIRAL AGENTS; APOLIPOPROTEIN A-I; BILIRUBIN; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HAPTOGLOBINS; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; LIVER CIRRHOSIS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0036906034     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.2002.00341.x     Document Type: Article

References (18)

1. Imbert-Bismut F, Ratziu V, Laurence Pieroni L, Charlotte F, Benhamou Y, Poynard T for the MULTIVIRC group. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study. Lancet 2001; 357: 1069-75.
2. Friedman SL. Evaluation of fibrosis and hepatitis C. Am J Med 1999; 107: 27S-30S.
3. Poynard T, Ratziu V, Benhamou Y, Di Martino VD, Bedossa P, Opolon P. Fibrosis in patients with chronic hepatitis C. detection and significance. Semin Liver Dis 2000; 20: 47-55.
4. Saadeh S, Cammell G, Carey WD, Younossi Z, Barnes D, Easley K. The role of liver biopsy in chronic hepatitis C. Hepatology 2001; 33: 196-200.
5. Degos F, Daurat V, Chevret S et al. Reinforced regimen of interferon alfa 2a reduces the incidence of cirrhosis in patients with chronic hepatitis C. A multicenter randomized trial. J Hepatol 1998; 29: 224-32.
6. Knodell KG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435.
7. The METAVIR cooperative group. Inter- and intra-observer variation in the assessment of liver biopsy of chronic hepatitis C. Hepatology 1994; 20 (1): 15-20.
8. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24 (2): 289-93.
9. Guechot J, Laudat A, Loria A, Serfaty L, Poupon R, Giboudeau J. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem 1996; 42: 558-63.
10. Wong VS, Hughes V, Trull A, Wight DG, Petrik J, Alexander GJ. Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection. J Viral Hepat 1998; 5: 187-92.
11. Hintze JL. NCSS 97 User Guide. Number Cruncher Statistical Systems: Kaysville, Utah 1997.
12. Sobesky R, Mathurin P, Charlotte F et al. Modeling the impact of alfa interferon treatment on liver fibrosis progression in chronic hepatitis C. A dynamic view. Gastroenterology 1999; 116: 378-86.
13. Shiratori Y, Imazeki F, Moriyama M et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132: 517-24.
14. Poynard T, McHutchison J, Davis GL et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000; 32: 1131-7.
15. Rosenberg W, Burt A, Becka M, Voelker M, Arthur M, European Liver Consortium. Automated assays of serum markers of liver fibrosis predict histological hepatic fibrosis. Hepatology 2000; 32: 183 (Abstract).
16. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: Results of a prospective nationwide survey. Hepatology 2000; 32: 477-481.
17. Poynard T, Lebrec D. The inconvenience of investigations used in hepatology: Patients' and hepatologists' opinions. Liver 1982; 2: 369-75.
18. Poynard T, Ratziu V, Bedossa P. Appropriateness of liver biopsy. Can J Gastroenterol 2000; 14: 543-548.